{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T09:49:23Z","timestamp":1785750563368,"version":"3.56.0"},"reference-count":89,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["22477106"],"award-info":[{"award-number":["22477106"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Taishan Scholars Program","award":["tsqn202408314"],"award-info":[{"award-number":["tsqn202408314"]}]},{"name":"Special Foundation of Yantai for Leading Talents above Provincial Level"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2026,8,3]]},"DOI":"10.1080\/13543776.2026.2693536","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:15:58Z","timestamp":1782173758000},"page":"679-693","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["A patent review of GPR84 receptor antagonists (2020\u2013present)"],"prefix":"10.1080","volume":"36","author":[{"given":"Tianyu","family":"Mi","sequence":"first","affiliation":[{"name":"Jiangxi University of Chinese Medicine","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Yin","sequence":"additional","affiliation":[{"name":"Jiangxi University of Chinese Medicine","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhai","family":"Chen","sequence":"additional","affiliation":[{"name":"Jiangxi University of Chinese Medicine","place":["Nanchang, China"]},{"name":"Bohai Rim Advanced Research Institute for Drug Discovery","place":["Yantai, China"]},{"name":"Chinese Academy of Sciences","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fajun","family":"Nan","sequence":"additional","affiliation":[{"name":"Bohai Rim Advanced Research Institute for Drug Discovery","place":["Yantai, China"]},{"name":"Chinese Academy of Sciences","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.2001.4520"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.69.6.1045"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M608019200"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.420042"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1039\/C7MD00130D"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38985-6"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01339"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.106047"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2024.111150"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16066"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1745-7580-4-5"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/glia.20506"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2015.01.010"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2012.01.001"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01419"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx091"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-021-00825-y"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-023-01080-z"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2018.01.009"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3558-14.2015"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00394-017-1456-5"},{"key":"e_1_3_5_24_1","unstructured":"Philbrook P Ochoa A Dean M. Board of supervisors of Louisiana state University and agricultural and mechanical college. Compositions comprising G protein-coupled receptor GPR84 antagonists for the treatment of cancer. WO2023076668.2023."},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10841-2"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01388-6"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03879-4"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41201-0"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15248"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2026.118561"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01378"},{"key":"e_1_3_5_32_1","unstructured":"Labeguere FG Newsome GJR. Galapagos NV. Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders. WO2013092791. 2013."},{"key":"e_1_3_5_33_1","unstructured":"Brys RCX Dupont S. Galapagos NV. Screening methods to identify compounds useful in the prevention and\/or treatment of inflammatory conditions. WO2013092793. 2013."},{"key":"e_1_3_5_34_1","unstructured":"Labeguere F Alvey L Newsome G et al. Galapagos NV. Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (GPR84 antagonists). WO2014095798. 2014."},{"key":"e_1_3_5_35_1","article-title":"Galapagos NV. Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders","author":"Menet CJM","year":"2016","unstructured":"Menet CJM, Doyon J-O, Claes PIRA, et al. Galapagos NV. Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders. WO2016169911. 2016.","journal-title":"WO2016169911"},{"key":"e_1_3_5_36_1","article-title":"Galapagos NV. Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders","author":"Doyon J-O","year":"2015","unstructured":"Doyon J-O, De Wachter MMP, Tricarico GA, et al. Galapagos NV. Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders. WO2015197550. 2015.","journal-title":"WO2015197550"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00272"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx002.734"},{"key":"e_1_3_5_39_1","unstructured":"Brys RCX Clement-Lacroix P De Vos SIJ et al. Galapagos NV. Compounds that antagonize GPR84 and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases. WO2019096944. 2019."},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9041140"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01794-2022"},{"key":"e_1_3_5_42_1","unstructured":"Galapagos refocuses pipeline and rightsizes operations: Galapagos. 2021. Available from: https:\/\/www.glpg.com\/press-release\/2096\/galapagos-refocuses-pipeline-and-rightsizes-operations"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2023-0221LE"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-025-01248-9"},{"key":"e_1_3_5_45_1","article-title":"Bayer Pharma Aktiengesellschaft. Inhibitors and antagonists of GPR84 for use in prevention and\/or treatment of endometriosis","author":"Sacher F","year":"2018","unstructured":"Sacher F, Obendorf M, Langer G, et al. Bayer Pharma Aktiengesellschaft. Inhibitors and antagonists of GPR84 for use in prevention and\/or treatment of endometriosis. WO2018210822. 2018.","journal-title":"WO2018210822"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-18159-3"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-38539-1"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175960"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1159\/000514887"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114288"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1021\/jacsau.3c00435"},{"key":"e_1_3_5_52_1","unstructured":"Zhang X Zang Y Wei W et al. Humanwell healthcare (Group) Co. Ltd. Preparation of dihydropyrimidoisoquinolinone derivatives and its application. CN115197216. 2022."},{"key":"e_1_3_5_53_1","unstructured":"Zhang X Zang Y Cai L et al. Humanwell healthcare (Group) Co. Ltd. GPR84 antagonist and preparation method therefor and application. WO2022194267. 2022."},{"key":"e_1_3_5_54_1","unstructured":"Zhang X Zang Y Wei W et al. Wuhan Humanwell innovative drug research and development center limited company. Tricyclic compound used as GPR84 antagonist. WO2022268088. 2022."},{"key":"e_1_3_5_55_1","unstructured":"Panknin O Sacher F Schmidt N et al. Bayer Aktiengesellschaft. Preparation of furoindazole derivatives as GPR84 antagonists. WO2021122415. 2021."},{"key":"e_1_3_5_56_1","unstructured":"Panknin O Sacher F Langer G et al. Bayer Aktiengesellschaft. Furoindazole derivatives as antagonists or inhibitors of GPR84. WO2022229061. 2022."},{"key":"e_1_3_5_57_1","unstructured":"Panknin O Sacher F Schmidt N et al. Bayer Aktiengesellschaft. Furoindazole derivatives as GPR84 antagonists and their preparation. WO2022179940. 2022."},{"key":"e_1_3_5_58_1","unstructured":"Sacher F Nagel J Miyatake Ondozabal H et al. Bayer Aktiengesellschaft. Furoindazole derivatives for the treatment of pain. WO2024083705. 2024."},{"key":"e_1_3_5_59_1","unstructured":"Pharmaceuticals \u2013\u2013 pipeline overview and progress: Bayer pharmaceuticals. 2025. Available from: https:\/\/www.bayer.com\/sites\/default\/files\/ph-rd-pipeline-2025-10-30-final.pdf"},{"key":"e_1_3_5_60_1","unstructured":"Yu T Xu C Zhou X et al. Guangzhou Unirise pharmaceutical Co. Ltd. Tricyclic compound and preparation method and use therefor. WO2024140968. 2024."},{"key":"e_1_3_5_61_1","unstructured":"Yu T Yang W Xu C et al. Guangzhou Unirise pharmaceutical Co. Ltd. Preparation method of benzoindazole derivative as GPR84 antagonist and their application. CN120230088. 2025."},{"key":"e_1_3_5_62_1","unstructured":"Yu T Xu C Zhou X et al. Guangzhou Unirise pharmaceutical Co. Ltd. Tricyclic pyrazole compounds as GPR84 antagonists and their preparation pharmaceutical compositions and use in the treatment of diseases. WO2024140969. 2024."},{"key":"e_1_3_5_63_1","unstructured":"Yu T Xu C Yang W et al. Guangzhou Unirise pharmaceutical Co. Ltd. Preparation of triazole based GPR84 antagonists and their application. CN120230087. 2025."},{"key":"e_1_3_5_64_1","unstructured":"Abbott S Deleseleuc M Martel J et al. Liminal biosciences limited. Preparation of heteroaromatics as GPR84 antagonists and uses thereof. WO2022167457. 2022."},{"key":"e_1_3_5_65_1","unstructured":"Abbott S De Leseleuc M Martel J et al. Liminal biosciences limited. Preparation of aryl-triazolyl and related GPR84 antagonists and uses thereof. WO2024028364. 2024."},{"key":"e_1_3_5_66_1","unstructured":"Abbott S De Leseleuc M Martel J et al. Liminal biosciences limited. Preparation of substituted heteroaryl carboxamide and related GPR84 antagonists and uses thereof. WO2024028363. 2024."},{"key":"e_1_3_5_67_1","unstructured":"Abbott S Deleseleuc M Martel J et al. Liminal biosciences limited. Preparation of heteroaromatics as GPR84 antagonists and uses thereof. WO2022167445. 2022."},{"key":"e_1_3_5_68_1","unstructured":"Abbott S De Leseleuc M Martel J. Liminal biosciences limited. Preparation of substituted pyridone GPR84 antagonists and uses thereof. WO2024028365. 2024."},{"key":"e_1_3_5_69_1","unstructured":"Nan F Xie X Chen L et al. Shanghai Institute of materia medica Chinese Academy of sciences. GPR84 receptor antagonist preparation and application. WO2018161831. 2018."},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01813"},{"key":"e_1_3_5_71_1","unstructured":"Nan F Xie X Li S et al. Shanghai Institute of materia medica Chinese Academy of sciences. Asymmetric GPR84 antagonist and use thereof. WO2023284794. 2023."},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00053"},{"key":"e_1_3_5_73_1","unstructured":"Nan F Xie X Xiao Y et al. Shanghai Institute of materia medica Chinese Academy of sciences. Application of biphenyl phosphate compound as GPR84 antagonist. WO2020007342. 2020."},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c00359"},{"key":"e_1_3_5_75_1","unstructured":"Nan F Xie X Li S et al. Shanghai Institute of materia medica Chinese Academy of sciences. Preparation and use of fluorescent probe targeting GPR84 receptor. WO2025040155. 2025."},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.1c00151"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00804"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.70379"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.101932"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c01923"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/pro.4792"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.118.250068"},{"key":"e_1_3_5_83_1","unstructured":"PBI-4050 [Internet]. Cortellis drug discovery intelligence: Clarivate. Available from: https:\/\/www.cortellis.cn\/drugdiscovery\/entity\/drug\/715284\/product"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00663-2018"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69675-8"},{"key":"e_1_3_5_86_1","unstructured":"PBI-4547 [Internet]. Cortellis drug discovery intelligence: Clarivate. Available from: https:\/\/www.cortellis.cn\/drugdiscovery\/entity\/drug\/863167\/product"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c02335"},{"key":"e_1_3_5_88_1","article-title":"University of Copenhagen. Preparation of polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as GPR84 antagonists","author":"Ulven T","year":"2022","unstructured":"Ulven T, Ieremias L, Manandhar A. University of Copenhagen. Preparation of polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as GPR84 antagonists. WO2022263676. 2022.","journal-title":"WO2022263676"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115190"},{"key":"e_1_3_5_90_1","unstructured":"Xu F Liu Y Wang J. Ganjiang traditional Chinese medicine innovation center. Application of chalcone derivative psoralen and GPR84 antagonist or drug thereof. CN120501730. 2025."},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2025.120575"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2693536","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13543776.2026.2693536","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2693536","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T09:34:04Z","timestamp":1785749644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2026.2693536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":89,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,3]]}},"alternative-id":["10.1080\/13543776.2026.2693536"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2026.2693536","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-01-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}